JP2015504041A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015504041A5 JP2015504041A5 JP2014547490A JP2014547490A JP2015504041A5 JP 2015504041 A5 JP2015504041 A5 JP 2015504041A5 JP 2014547490 A JP2014547490 A JP 2014547490A JP 2014547490 A JP2014547490 A JP 2014547490A JP 2015504041 A5 JP2015504041 A5 JP 2015504041A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- inhibitor
- composition
- subject
- enolase
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161570366P | 2011-12-14 | 2011-12-14 | |
| US61/570,366 | 2011-12-14 | ||
| US201261652738P | 2012-05-29 | 2012-05-29 | |
| US61/652,738 | 2012-05-29 | ||
| PCT/US2012/069767 WO2013090732A2 (en) | 2011-12-14 | 2012-12-14 | Collateral gene inactivation biomarkers and targets for cancer therapy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018192504A Division JP7193296B2 (ja) | 2011-12-14 | 2018-10-11 | 癌治療のための副次的遺伝子不活性化バイオマーカーおよび標的 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015504041A JP2015504041A (ja) | 2015-02-05 |
| JP2015504041A5 true JP2015504041A5 (show.php) | 2016-02-04 |
| JP6820653B2 JP6820653B2 (ja) | 2021-01-27 |
Family
ID=48613367
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014547490A Active JP6820653B2 (ja) | 2011-12-14 | 2012-12-14 | 癌治療のための副次的遺伝子不活性化バイオマーカーおよび標的 |
| JP2018192504A Active JP7193296B2 (ja) | 2011-12-14 | 2018-10-11 | 癌治療のための副次的遺伝子不活性化バイオマーカーおよび標的 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018192504A Active JP7193296B2 (ja) | 2011-12-14 | 2018-10-11 | 癌治療のための副次的遺伝子不活性化バイオマーカーおよび標的 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US9452182B2 (show.php) |
| EP (2) | EP3603678A3 (show.php) |
| JP (2) | JP6820653B2 (show.php) |
| KR (2) | KR102144452B1 (show.php) |
| CN (3) | CN109276717B (show.php) |
| DK (1) | DK2790738T3 (show.php) |
| ES (1) | ES2746058T3 (show.php) |
| HR (1) | HRP20191607T1 (show.php) |
| HU (1) | HUE045359T2 (show.php) |
| IN (1) | IN2014DN05803A (show.php) |
| WO (1) | WO2013090732A2 (show.php) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3094341B1 (en) | 2014-01-13 | 2019-10-02 | Berg LLC | Enolase 1 (eno1) compositions and uses thereof |
| CN104894229A (zh) * | 2014-03-04 | 2015-09-09 | 中南大学 | 己糖激酶2作为鼻咽癌放疗预后预测的生物标志物 |
| EP3240566B1 (en) * | 2014-12-31 | 2020-07-22 | Development Center for Biotechnology | Humanized alpha-enolase specific antibodies and methods of uses in cancer therapy |
| PT3268376T (pt) | 2015-03-09 | 2022-04-08 | Univ Texas | Inibidores de enolase e métodos de tratamento com os mesmos |
| WO2017074788A1 (en) * | 2015-10-27 | 2017-05-04 | The Broad Institute Inc. | Compositions and methods for targeting cancer-specific sequence variations |
| CA2937896A1 (en) * | 2016-08-02 | 2018-02-02 | Universite De Montreal | Use of mubritinib for the treatment of poor prognosis acute myeloid leukemia |
| CN107217054B (zh) * | 2017-04-25 | 2020-08-14 | 中山大学肿瘤防治中心 | G6pd基因及其表达产物在治疗结直肠癌中的应用 |
| CN107460250B (zh) * | 2017-09-28 | 2020-07-28 | 郑州大学第一附属医院 | 基于kif14、kif15和kif20a基因的透明细胞肾癌诊断试剂盒及其使用方法 |
| US11554262B2 (en) * | 2019-02-26 | 2023-01-17 | Novocure Gmbh | Determining a frequency for TTFields treatment based on an electrical characteristic of targeted cancer cells |
| SG11202109531UA (en) * | 2019-03-29 | 2021-09-29 | Univ Texas | Compounds with anti-tumor activity against cancer cells bearing her2 exon 21 insertions |
| EP3976195A4 (en) * | 2019-05-28 | 2023-10-18 | The Regents Of The University Of California | METHODS OF TREATMENT OF SMALL CELL NEUROENDOCRINAL CANCERS AND ASSOCIATED CANCERS |
| WO2021150925A1 (en) * | 2020-01-24 | 2021-07-29 | Dana-Farber Cancer Institute, Inc. | Uses of biomarkers for improving immunotherapy |
| CN113567675B (zh) * | 2020-04-28 | 2023-09-22 | 苏州浚惠生物科技有限公司 | 用于肿瘤的己糖激酶2抑制剂液体活检伴随诊断和试剂盒 |
| AU2021356099A1 (en) * | 2020-10-06 | 2023-05-25 | European Molecular Biology Laboratory | Screening method for the identification of novel therapeutic compounds |
| EP4433089A1 (en) * | 2021-11-19 | 2024-09-25 | Institut Curie | Methods for the treatment of hrd cancer and brca-associated cancer |
| US20250320562A1 (en) * | 2022-06-10 | 2025-10-16 | The Children's Hospital Of Philadelphia | Alternatively spliced isoform in cancer and methods of use thereof |
| CN114751961B (zh) * | 2022-06-14 | 2022-09-20 | 中山大学孙逸仙纪念医院 | circ0005199-173aa蛋白及其在制备食管癌诊断产品中的应用 |
| CN115074445B (zh) * | 2022-08-09 | 2023-08-08 | 河北医科大学第二医院 | Eno3在肾癌诊断及治疗中的应用 |
| CN115825308B (zh) * | 2022-11-30 | 2023-06-09 | 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) | 鼻咽癌相关尿液标志物在制备用于鼻咽癌诊断/预后的产品中的应用 |
| CN116286828B (zh) * | 2023-05-12 | 2023-08-18 | 中国人民解放军军事科学院军事医学研究院 | 一种寡聚核酸siRNA及其在制备用于预防和治疗肝癌的药物中的应用 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5279721A (en) | 1993-04-22 | 1994-01-18 | Peter Schmid | Apparatus and method for an automated electrophoresis system |
| WO1998041648A2 (en) * | 1997-03-20 | 1998-09-24 | Variagenics, Inc. | Target genes for allele-specific drugs |
| US6046002A (en) | 1998-01-05 | 2000-04-04 | The Board Of Trustees Of The Leland Stanford Junior University | Highly parallel and sensitive method for identifying drugs and drug targets |
| US6200754B1 (en) | 1998-03-19 | 2001-03-13 | Variagenics, Inc. | Inhibitors of alternative alleles of genes encoding products that mediate cell response to environmental changes |
| EP1392639B1 (en) | 2001-05-03 | 2008-09-17 | Galileo Laboratories, Inc. | Pyruvate derivatives |
| AU2003220201A1 (en) | 2002-03-26 | 2003-10-13 | Indiana University | Purification and cloning of nmn adenylyltranserase and its therapeutic use |
| DE602005014651D1 (de) | 2004-08-30 | 2009-07-09 | Interstitial Therapeutics | Medizinischer stent mit atp-synthesehemmern |
| EP2295601A1 (en) * | 2005-02-10 | 2011-03-16 | Oncotherapy Science, Inc. | Method of diagnosing bladder cancer |
| WO2007072219A2 (en) * | 2005-09-21 | 2007-06-28 | Aurelium Biopharma Inc. | Alpha enolase-directed diagnostics and therapeutics for cancer and chemotherapeutic drug resistance |
| WO2007104011A2 (en) | 2006-03-08 | 2007-09-13 | University Of Maryland, Baltimore | Inhibition of microtubule protrusion in cancer cells |
| CN101583622B (zh) | 2006-11-02 | 2012-11-07 | 舒泰神（北京）生物制药股份有限公司 | 用于破坏与泛素化相关的酶的相互作用的抑制剂和其应用 |
| TWI615403B (zh) * | 2007-02-21 | 2018-02-21 | 腫瘤療法 科學股份有限公司 | 表現腫瘤相關抗原之癌症的胜肽疫苗 |
| US8178317B2 (en) | 2007-05-01 | 2012-05-15 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for identifying transforming and tumor suppressor genes |
| CN102225201A (zh) * | 2010-05-11 | 2011-10-26 | 中国医学科学院基础医学研究所 | 糖酵解抑制剂的新用途 |
-
2012
- 2012-12-14 CN CN201810965939.XA patent/CN109276717B/zh active Active
- 2012-12-14 KR KR1020147019549A patent/KR102144452B1/ko active Active
- 2012-12-14 ES ES12858619T patent/ES2746058T3/es active Active
- 2012-12-14 CN CN202210284955.9A patent/CN115177727A/zh active Pending
- 2012-12-14 WO PCT/US2012/069767 patent/WO2013090732A2/en not_active Ceased
- 2012-12-14 JP JP2014547490A patent/JP6820653B2/ja active Active
- 2012-12-14 EP EP19191479.5A patent/EP3603678A3/en active Pending
- 2012-12-14 IN IN5803DEN2014 patent/IN2014DN05803A/en unknown
- 2012-12-14 US US14/365,367 patent/US9452182B2/en active Active
- 2012-12-14 EP EP12858619.5A patent/EP2790738B1/en active Active
- 2012-12-14 HU HUE12858619A patent/HUE045359T2/hu unknown
- 2012-12-14 KR KR1020207022890A patent/KR102355121B1/ko active Active
- 2012-12-14 DK DK12858619.5T patent/DK2790738T3/da active
- 2012-12-14 CN CN201280069681.6A patent/CN104144707B/zh active Active
- 2012-12-14 HR HRP20191607 patent/HRP20191607T1/hr unknown
-
2018
- 2018-10-11 JP JP2018192504A patent/JP7193296B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015504041A5 (show.php) | ||
| JP6820653B2 (ja) | 癌治療のための副次的遺伝子不活性化バイオマーカーおよび標的 | |
| Chipumuro et al. | CDK7 inhibition suppresses super-enhancer-linked oncogenic transcription in MYCN-driven cancer | |
| Lu et al. | LncRNA SNHG16 functions as an oncogene by sponging MiR-4518 and up-regulating PRMT5 expression in glioma | |
| Yan et al. | Long noncoding RNA H19/miR-675 axis promotes gastric cancer via FADD/Caspase 8/Caspase 3 signaling pathway | |
| Wee et al. | EZH2-mediated inactivation of IFN-γ-JAK-STAT1 signaling is an effective therapeutic target in MYC-driven prostate cancer | |
| JP2019011365A5 (show.php) | ||
| Chen et al. | miR-21-5p confers doxorubicin resistance in gastric cancer cells by targeting PTEN and TIMP3 | |
| Wu et al. | Knockdown of lncRNA MIAT inhibits proliferation and cisplatin resistance in non-small cell lung cancer cells by increasing miR-184 expression | |
| Yoon et al. | PHGDH preserves one-carbon cycle to confer metabolic plasticity in chemoresistant gastric cancer during nutrient stress | |
| Pierro et al. | The NSD2 p. E1099K mutation is enriched at relapse and confers drug resistance in a cell context–dependent manner in pediatric acute lymphoblastic leukemia | |
| Sui et al. | Propofol suppresses gastric cancer tumorigenesis by modulating the circular RNA-PVT1/miR-195-5p/E26 oncogene homolog 1 axis | |
| Wang et al. | Synthetic microRNA cassette dosing: pharmacokinetics, tissue distribution and bioactivity | |
| Lang et al. | Musashi1 promotes non-small cell lung carcinoma malignancy and chemoresistance via activating the Akt signaling pathway | |
| Lailler et al. | ERK1/2 signaling regulates the immune microenvironment and macrophage recruitment in glioblastoma | |
| Harb-De la Rosa et al. | The role of epigenetics in kidney malignancies | |
| Moharram et al. | T-cell acute lymphoblastic leukemia cells display activation of different survival pathways | |
| Wu et al. | Circular RNA CDR1as alleviates cisplatin-based chemoresistance by suppressing MiR-1299 in ovarian cancer | |
| Huang et al. | lncRNA DGCR5 inhibits the proliferation of colorectal cancer cells by downregulating miR-21 | |
| Zhang et al. | MicroRNA‑138 modulates glioma cell growth, apoptosis and invasion through the suppression of the AKT/mTOR signalling pathway by targeting CREB1 | |
| Wang et al. | Associations between SOX2 and miR-200b expression with the clinicopathological characteristics and prognosis of patients with glioma | |
| Bagaloni et al. | Metabolic switch and cytotoxic effect of metformin on Burkitt lymphoma | |
| Bai et al. | Tetraarsenic tetrasulfide triggers ROS-induced apoptosis and ferroptosis in B-cell acute lymphoblastic leukaemia by targeting HK2 | |
| Nishioka et al. | Imatinib causes epigenetic alterations of PTEN gene via upregulation of DNA methyltransferases and polycomb group proteins | |
| Stachyra et al. | Signaling pathways in gliomas |